汎用インフルエンザワクチン:世界におけるワクチンの機会分析

【英語タイトル】MarketVIEW: Universal influenza vaccines - Vaccine opportunity assessment

VacZine Analyticsが出版した調査資料(DATA6120714)・商品コード:DATA6120714
・発行会社(調査会社):VacZine Analytics
・発行日:2016年8月
・ページ数:※お問い合わせください。
・レポート言語:英語
・レポート形式:PDF、Excel
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD3,800 ⇒換算¥414,200見積依頼/購入/質問フォーム
Forecast Model (Excel)USD3,800 ⇒換算¥414,200見積依頼/購入/質問フォーム
PDF+ExcelUSD7,599 ⇒換算¥828,291見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Executive presentation + commercial forecast model

【レポートの目次】

※レポートの目次⇒http://www.vaczine-analytics.com/VAMV020_TOC_160725.pdf

Author’s note
Executive summary
Key commercial model outputs
Universal vaccine: predicted pandemic primer demand to 2035 (doses 000s)
Universal vaccine: predicted pandemic primer value to 2035 ($ 000s)
Predicted pandemic primer value to 2035 per country ($ 000s)
Predicted seasonal primer demand to 2035 (19-65 yrs) (doses 000s)
Predicted seasonal primer value to 2035 (19-65 yrs) ($ 000s)
Predicted seasonal primer demand to 2035 (>65 yrs) (doses 000s)
Predicted seasonal primer value to 2035 (>65 yrs) ($ 000s)
Peak year revenues per country per age: seasonal primer ($ 000s)
Predicted seasonal primer/standalone value to 2035 (19 - 65 yrs) ($ 000s)
The limitations of current influenza vaccines: review of current challenges
Influenza vaccine mismatching and reduced efficacy
Current innovations in influenza vaccines: review of major licensed products
Licensed influenza vaccines: innovation areas
Influenza vaccines: product innovations - strain coverage
Influenza vaccines: product innovations - HA content
Influenza vaccines: product innovations - delivery systems
Influenza vaccines: product innovations - production systems
Influenza vaccines: product innovations - adjuvantation
Innovation examples in licensed influenza vaccines: increment analysis
Influenza vaccine product innovations improve pricing at first introduction
Other innovation areas
Future innovation in influenza vaccines - review of R&D pipeline
Searching for further innovation in influenza vaccines: methodology
Innovation search: key findings
Novel influenza vaccine pipeline: by development phase
Novel influenza vaccine pipeline: by antigen type
Novel influenza vaccine pipeline: by organisation type
Novel influenza vaccine pipeline: by innovation/segment type
Universal influenza vaccines: the next wave of innovation?
Potential benefits to universal influenza vaccines
Overview of approaches: to universal vaccines
Viral targets for broadly reactive universal vaccines
Mechanisms of virus neutralization: summary
Classification of viral targets in terms of response
Universal approaches: points to note
Universal vaccine pipeline by Phase
Universal influenza vaccine programs at preclinical stages
Universal influenza vaccine programs at clinical stages
Focus on BiondVax: multimeric-001
Multimeric-001 (BiondVax) - Phase II priming data
BiondVax: latest update for M-001
Universal vaccines: other notable programs (SEEK)
Universal vaccines: other notable programs (Inovio)
Other innovations in influenza vaccines (seasonal vaccines)
Other innovations in influenza vaccines (pandemic vaccines)
Challenges in technical and regulatory assessment
Universal influenza vaccines: modelling potential demand/commercial value
Universal influenza vaccine opportunity: target product profile (TPP)
Universal influenza antigens: possible use scenarios
Universal influenza vaccine - modelling rationale
Predicted launch sequence: M-001 (BiondVax)
M-001 (BiondVax) pandemic primer - estimated launch
Overall modelling methodology: pandemic primer
Framework for targeting pandemic primer influenza vaccine (US)
Vaccination target groups for a pandemic primer vaccine
Estimated numbers in vaccination target groups (US)
Estimated numbers in vaccination tiers (US)
Tier1 equivalent populations: outside US
Manufacturers of vaccines and antivirals
Assessing Tier1 stockpile size – Europe
Assessing Tier1 yearly demand
Overall modelling methodology: seasonal primer
M-001: Standalone vaccine?
Pricing methodology
Model caveats and limitations
Appendix 1
Novel influenza vaccine technologies by type/phase
Countries included in seasonal demand forecast model
Novel inactivated virus vaccines
Novel live attenuated influenza virus vaccines
Novel vectored influenza vaccines
Novel recombinant influenza peptides
Novel recombinant influenza proteins
Novel recombinant influenza DNA
Novel influenza immunoglobulin
Bibliography
Disclaimer
About VacZine Analytics
Slide number = 98


【レポートのキーワード】

汎用インフルエンザワクチン

★調査レポート[汎用インフルエンザワクチン:世界におけるワクチンの機会分析] (コード:DATA6120714)販売に関する免責事項を必ずご確認ください。
★調査レポート[汎用インフルエンザワクチン:世界におけるワクチンの機会分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆